

# Paulette Bioulac-Sage

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/455539/publications.pdf>

Version: 2024-02-01

89  
papers

9,736  
citations

66315

42  
h-index

48277

88  
g-index

91  
all docs

91  
docs citations

91  
times ranked

8559  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatocellular adenoma: what we know, what we do not know, and why it matters. <i>Histopathology</i> , 2022, 80, 878-897.	1.6	21
2	Malignant transformation of hepatocellular adenoma. <i>JHEP Reports</i> , 2022, 4, 100430.	2.6	4
3	Risk factors for bleeding hepatocellular adenoma. <i>Liver International</i> , 2022, 42, 947-948.	1.9	1
4	Long-term Evolution of Hepatocellular Adenomas at MRI Follow-up. <i>Radiology</i> , 2021, 298, E57-E58.	3.6	1
5	Hepatocellular adenomas: the expanding epidemiology. <i>Histopathology</i> , 2021, 79, 20-22.	1.6	4
6	Hepatocellular Adenoma Risk Factors of Hemorrhage: Size Is Not the Only Concern!. <i>Annals of Surgery</i> , 2021, 274, 843-850.	2.1	15
7	Proteomic Profiling of Hepatocellular Adenomas Paves the Way to Diagnostic and Prognostic Approaches. <i>Hepatology</i> , 2021, 74, 1595-1610.	3.6	7
8	Hepatocellular adenoma with a double mutation <i>HNF1A</i> and <i>IDH1</i> in a patient with Ollier disease. <i>Liver International</i> , 2021, 41, 3009-3010.	1.9	0
9	Predictive Patterns of Glutamine Synthetase Immunohistochemical Staining in CTNNB1-mutated Hepatocellular Adenomas. <i>American Journal of Surgical Pathology</i> , 2021, 45, 477-487.	2.1	28
10	Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 71, 164-182.	3.6	129
11	Malignant transformation of liver fatty acid binding protein-deficient hepatocellular adenomas: histopathologic spectrum of a rare phenomenon. <i>Modern Pathology</i> , 2020, 33, 665-675.	2.9	29
12	miR-4510 blocks hepatocellular carcinoma development through <i>RAF1</i> targeting and RAS/RAF/MEK/ERK signalling inactivation. <i>Liver International</i> , 2020, 40, 240-251.	1.9	27
13	BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. <i>Journal of Hepatology</i> , 2020, 72, 924-936.	1.8	44
14	ASS1 Overexpression: A Hallmark of Sonic Hedgehog Hepatocellular Adenomas; Recommendations for Clinical Practice. <i>Hepatology Communications</i> , 2020, 4, 809-824.	2.0	33
15	Histology of portal vascular changes associated with idiopathic non-cirrhotic portal hypertension: nomenclature and definition. <i>Histopathology</i> , 2019, 74, 219-226.	1.6	49
16	Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. <i>Gastroenterology</i> , 2019, 157, 760-776.	0.6	141
17	Unclassified hepatocellular adenoma expressing ASS1 associated with inflammatory hepatocellular adenomas. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, e63-e67.	0.7	7
18	A $\beta$ -Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease. <i>Hepatology</i> , 2019, 70, 231-240.	3.6	75

#	ARTICLE	IF	CITATIONS
19	Repeat surgery in HNF1alpha-inactivated adenomatosis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 460-467.	0.7	2
20	Porto-sinusoidal vascular disease: proposal and description of a novel entity. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 399-411.	3.7	149
21	OATP1/B3 and MRP3 expression in hepatocellular adenoma predicts Gdâ€œEOBâ€œDTPA uptake and correlates with risk of malignancy. <i>Liver International</i> , 2019, 39, 158-167.	1.9	29
22	A difficult case of Î²-cateninâ€œmutated hepatocellular adenoma: a lesson for diagnosis. <i>Histopathology</i> , 2019, 74, 355-357.	1.6	3
23	Snapshot summary of diagnosis and management of hepatocellular adenoma subtypes. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 12-19.	0.7	11
24	New MRI features improve subtype classification of hepatocellular adenoma. <i>European Radiology</i> , 2019, 29, 2436-2447.	2.3	30
25	Unexpected discovery of small <sc>HNF</sc>Î±-inactivated hepatocellular adenoma in pathological specimens from patients resected for liver tumours. <i>Liver International</i> , 2018, 38, 1273-1279.	1.9	3
26	Vascular liver lesions: contemporary views on long-recognized entities. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 1-2.	1.4	6
27	Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress. <i>Nature Communications</i> , 2018, 9, 5235.	5.8	118
28	Hepatocellular nodules in vascular liver diseases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 33-44.	1.4	37
29	Collision of hepatocellular nodules in vascular livers: A medical challenge. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, e83-e85.	0.7	3
30	Benign Hepatocellular Tumors. , 2018, , 507-527.		2
31	Hepatocellular adenoma: Classification, variants and clinical relevance. <i>Seminars in Diagnostic Pathology</i> , 2017, 34, 112-125.	1.0	67
32	Malignant transformation of a Î²-catenin inflammatory adenoma due to an S45 Î²-cateninâ€œactivating mutation present 12 years before. <i>Human Pathology</i> , 2017, 62, 122-125.	1.1	13
33	Hepatocellular Adenomas. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 253-272.	1.0	27
34	Focal Î²-catenin mutation identified on formalinâ€œfixed and paraffinâ€œembedded inflammatory hepatocellular adenomas. <i>Histopathology</i> , 2017, 71, 989-993.	1.6	14
35	Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. <i>Journal of Hepatology</i> , 2017, 67, 727-738.	1.8	525
36	Germline and somatic DICER1 mutations in familial and sporadic liver tumors. <i>Journal of Hepatology</i> , 2017, 66, 734-742.	1.8	31

#	ARTICLE	IF	CITATIONS
37	CYP1A2 is a predictor of HCC recurrence in HCV-related chronic liver disease: A retrospective multicentric validation study. <i>Digestive and Liver Disease</i> , 2017, 49, 434-439.	0.4	9
38	Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. <i>Gastroenterology</i> , 2017, 152, 880-894.e6.	0.6	290
39	Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. <i>Nature Communications</i> , 2017, 8, 1315.	5.8	228
40	Argininosuccinate synthase 1 (ASS1): A marker of unclassified hepatocellular adenoma and high bleeding risk. <i>Hepatology</i> , 2017, 66, 2016-2028.	3.6	75
41	Genotype-phenotype correlation of CTNNB1 mutations reveals different $\beta$ -catenin activity associated with liver tumor progression. <i>Hepatology</i> , 2016, 64, 2047-2061.	3.6	222
42	Liver transplantation for adenomatosis: European experience. <i>Liver Transplantation</i> , 2016, 22, 516-526.	1.3	41
43	Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis. <i>Modern Pathology</i> , 2016, 29, 43-50.	2.9	45
44	Simultaneous Occurrence of Focal Nodular Hyperplasia and HNF1A-inactivated Hepatocellular Adenoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1296-1300.	2.1	10
45	Hepatocellular adenoma management: Call for shared guidelines and multidisciplinary approach. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 180-187.	0.7	24
46	Well-differentiated hepatocellular neoplasm of uncertain malignant potential. <i>Human Pathology</i> , 2015, 46, 634-635.	1.1	22
47	Hepatocellular nodules expressing markers of hepatocellular adenomas in Budd-Chiari syndrome and other rare hepatic vascular disorders. <i>Journal of Hepatology</i> , 2015, 63, 1173-1180.	1.8	86
48	Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas. <i>Gut</i> , 2015, 64, 820-829.	6.1	127
49	Pictures of focal nodular hyperplasia and hepatocellular adenomas. <i>World Journal of Hepatology</i> , 2014, 6, 580.	0.8	18
50	Glutamine synthetase interpretation in hepatocellular adenoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 465, 495-496.	1.4	5
51	Malignant transformation of hepatocellular adenoma. <i>Hepatic Oncology</i> , 2014, 1, 421-431.	4.2	29
52	Polycystic ovary syndrome as a rare association with inflammatory hepatocellular adenoma: A case report. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, e107-e110.	0.7	3
53	Congenital hepatic fibrosis with multiple HNF1 $\alpha$ hepatocellular adenomas. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, e115-e116.	0.7	11
54	Hepatocellular adenomatosis: What should the term stand for!. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 132-136.	0.7	26

#	ARTICLE	IF	CITATIONS
55	Immunohistochemical pitfalls in the diagnosis of focal nodular hyperplasia and inflammatory hepatocellular adenoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 245-249.	0.7	10
56	Genomic Profiling of Hepatocellular Adenomas Reveals Recurrent FRK-Activating Mutations and the Mechanisms of Malignant Transformation. <i>Cancer Cell</i> , 2014, 25, 428-441.	7.7	240
57	Coexistence of inflammatory hepatocellular adenomas with HNF1 $\alpha$ -inactivated adenomas: is there an association?. <i>Histopathology</i> , 2014, 64, 890-895.	1.6	15
58	High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. <i>Nature Communications</i> , 2013, 4, 2218.	5.8	513
59	Benign hepatocellular nodules: What have we learned using the patho-molecular classification. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 322-327.	0.7	26
60	Hepatocellular Benign Tumors – From Molecular Classification to Personalized Clinical Care. <i>Gastroenterology</i> , 2013, 144, 888-902.	0.6	251
61	Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. <i>Journal of Hepatology</i> , 2013, 58, 350-357.	1.8	146
62	Focal Nodular Hyperplasia and Hepatocellular Adenoma around the World Viewed through the Scope of the Immunopathological Classification. <i>International Journal of Hepatology</i> , 2013, 2013, 1-12.	0.4	52
63	Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma. <i>Oncotmunology</i> , 2013, 2, e27090.	2.1	39
64	Value and Limits of Routine Histology Alone or Combined with Glutamine Synthetase Immunostaining in the Diagnosis of Hepatocellular Adenoma Subtypes on Surgical Specimens. <i>International Journal of Hepatology</i> , 2013, 2013, 1-8.	0.4	19
65	Beyond “Cirrhosis”: <i>American Journal of Clinical Pathology</i> , 2012, 137, 5-9.	0.4	103
66	Immunohistochemical Markers on Needle Biopsies Are Helpful for the Diagnosis of Focal Nodular Hyperplasia and Hepatocellular Adenoma Subtypes. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1691-1699.	2.1	118
67	Hepatocellular adenoma subtypes: the impact of overweight and obesity. <i>Liver International</i> , 2012, 32, 1217-1221.	1.9	109
68	GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. <i>Journal of Hepatology</i> , 2012, 56, 184-191.	1.8	354
69	Role of Contrast-Enhanced Sonography in Differentiation of Subtypes of Hepatocellular Adenoma: Correlation with MRI Findings. <i>American Journal of Roentgenology</i> , 2012, 199, 341-348.	1.0	58
70	Revisiting the Pathology of Resected Benign Hepatocellular Nodules Using New Immunohistochemical Markers. <i>Seminars in Liver Disease</i> , 2011, 31, 091-103.	1.8	112
71	Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. <i>Journal of Experimental Medicine</i> , 2011, 208, 1359-1366.	4.2	218
72	Hepatic resection for inflammatory hepatocellular adenomas: pathological identification of micronodules expressing inflammatory proteins. <i>Liver International</i> , 2010, 30, 149-154.	1.9	20

#	ARTICLE	IF	CITATIONS
73	Spectrum of <i>HNF1A</i> Somatic Mutations in Hepatocellular Adenoma Differs From That in Patients With <i>MODY3</i> and Suggests Genotoxic Damage. <i>Diabetes</i> , 2010, 59, 1836-1844.	0.3	57
74	Hepatocellular adenoma management and phenotypic classification: The Bordeaux experience. <i>Hepatology</i> , 2009, 50, 481-489.	3.6	394
75	Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. <i>Nature</i> , 2009, 457, 200-204.	13.7	437
76	Overexpression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology. <i>Liver International</i> , 2009, 29, 459-465.	1.9	143
77	Hepatocellular adenoma in advanced-stage fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 932-936.	0.8	25
78	MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. <i>Hepatology</i> , 2008, 47, 1955-1963.	3.6	634
79	Hepatocellular adenomas: Magnetic resonance imaging features as a function of molecular pathological classification. <i>Hepatology</i> , 2008, 48, 808-818.	3.6	277
80	The $\beta$ -catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules. <i>Journal of Hepatology</i> , 2008, 49, 61-71.	1.8	87
81	Association of <i>CYP1B1</i> Germ Line Mutations with Hepatocyte Nuclear Factor $\beta$ -Mutated Hepatocellular Adenoma. <i>Cancer Research</i> , 2007, 67, 2611-2616.	0.4	62
82	Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. <i>Hepatology</i> , 2007, 46, 740-748.	3.6	554
83	Genotype-phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC. <i>Hepatology</i> , 2006, 43, 515-524.	3.6	733
84	Clinical, Morphologic, and Molecular Features Defining So-Called Telangiectatic Focal Nodular Hyperplasias of the Liver. <i>Gastroenterology</i> , 2005, 128, 1211-1218.	0.6	207
85	Association of adenoma and focal nodular hyperplasia: experience of a single French academic center. <i>Comparative Hepatology</i> , 2003, 2, 6.	0.9	55
86	Familia liver adenomatosis associated with hepatocyte nuclear factor $\beta$ inactivation 1 The authors thank Leigh Pascoe for critical reading of the manuscript, Hne Blanch and Hung Bui of the CEPH/Fondation Jean Dausset for technical help in sequencing, and Drs. A. Saillant, E. Akodjenou, and E. Urvoas (Pediatric and Radiology Units, Hpitaux de Chartres, France) for referring patient B1 to E.J. and for performing liver ultrasound screening in family B.. <i>Gastroenterology</i> , 2003, 125, 1470-1475.	0.6	169
87	The identification of small nodules in liver adenomatosis. <i>Journal of Hepatology</i> , 2003, 39, 77-85.	1.8	42
88	Bi-allelic inactivation of <i>TCF1</i> in hepatic adenomas. <i>Nature Genetics</i> , 2002, 32, 312-315.	9.4	333
89	Liver Adenomatosis: Reappraisal, Diagnosis, and Surgical Management. <i>Annals of Surgery</i> , 2000, 231, 74.	2.1	163